CRSP Stock is currently the biggest gene editing stock by market cap and the one likely to have the first gene editing therapy approved and marketed. Exa-cel is pending a decision on December 8th for sickle cell disease or SCD and March 2024 for transfusion dependent beta thalassemia or TDT. A recent report looked at pricing exa-cel and lovo-cel, a gene therapy by Bluebird Bio that will also provide a cure for SCD. Both therapies have been given a "fair price estimate" midpoint of $1.7 million so we can now start estimating what cash flows might look like for the 25,000 eligible SCD patients and 7,000 eligible TDT patients. Investors in CRSP stock need to temper their expectations as there are quite a few unknowns remaining. If the exa-cel approval next month makes $CRSP stock move in either direction, expect that tide to move all gene editing stocks. The next gene editing stock to watch for an approved treatment should be Intellia. If you're invested in CRISPR Therapeutics stock, this video is a much-watch.

RESEARCH PIECES USED IN THIS VIDEO:
1. Revisiting the Three Biggest Gene Editing Stocks
https://www.nanalyze.com/2023/06/revi...
2. Beam Therapeutics Stock: A Leader in Gene Editing Tech?
https://www.nanalyze.com/2022/06/beam...
3. A Complete List of 27 Gene Editing Stocks
https://www.nanalyze.com/2022/06/comp...

CHAPTERS:
Intro
The founder of CRISPR Therapeutics
The gene editing patent battle
The exa-cel opportunity
CRISPR and Vertex
Lovo-cel and exa-cel
Potential profits for $CRSP
Valuing CRSP stock
BEAM and Intellia
ARK invests in gene editing
Conclusion

ABOUT US:
This video is brought to you by Nanalyze, a media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #stocks in a language that is future-proof and easy to understand.

Read all the Nanalyze Premium articles you'd like for free! Sign up for a 30-day trial of our monthly subscription with no strings attached: https://www.nanalyze.com/subscription...

DISCLAIMER: Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, along with independently researching and verifying, any information contained within our YouTube videos or on our website, whether for the purpose of making an investment or otherwise.

#GeneEditing
$BEAM
$CRSP
$NTLA
#techstocks